BSEResult1h ago · 14 Nov 2026, 02:29 pm
We are submitting the Un-Audited Financial Result along with Limited Review Report of the Company for Second Quarter and Half Year Ended as on 30th September, 2026
Lactose India Ltd · 524202
✦ AI SummaryResults
Lactose India Ltd has submitted its un-audited financial results for the second quarter and half year ended September 30, 2026, along with a limited review report from its independent auditor.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Lactose India Ltd - 524202 - Regulation 33 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations 2015 - Un-Audited Financial Results For The Second Quarter And Half Year Ended 30Th September, 2026
Attachments (1)
📄pdf
Download →
cf248790-5e5d-4cae-a297-f0386aa89cf9.pdf
View document text
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai‐ 400001
Scrip code‐ 524202
Subject: Regulation 33 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements), Regulations 2015 – Un‐Audited Financial
Results for the Second quarter and Half year ended 30th September, 2026
Dear Sir,
We are submitting the Un‐Audited Financial Result along with the Auditors’ Report of
Lactose (India) Limited for the Second quarter and half year ended 30th September,
2026.
The Meeting of the Board of Directors of the Company commenced at 12:00 noon and
concluded at 02:00 p.m.
Kindly take the same on record and oblige.
For Lactose (India) Limited
Atul Maheshwari
Managing Director
DIN: 00255202
Date: 14th November 2026
Place: Mumbai
Encl: As above
Independent Auditor’s Limited Review Report on Unaudited Financial Results of Lactose (India) Limited for
the quarter and half year ended on September 30, 2026, pursuant to the Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, as amended
The Board of Directors of
Lactose India Limited
1. We have reviewed the accompanying Statement of Unaudited Financial Results of Lactose India Limited (‘the
Company’) for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30,
2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of
Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended (‘the Regulation’).
2. This Statement, which is the responsibility of the Management and approved by the Company’s Board of
Directors, has been prepared in accordance with the recognition and measurement principles laid down in
Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under Section 133 of the
Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles
generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE)
2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by
the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to
obtain moderate assurance as to whether financial results are free of material misstatements. A review consists
of making inquiries, primarily of persons responsible for financial and accounting matters, and applying
analytical and other review procedures. A review is substantially less in scope than an audit conducted in
accordance with Standards on Auditing specified under Section 143(10) and consequently does not enable us
to obtain assurance that we would become aware of all significant matters that might be identified in an audit.
Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the
accompanying Statement, prepared in accordance with the recognition and measurement principles laid down
in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued
thereunder and other recognized accounting principles generally accepted in India has not disclosed the
information required to be disclosed in terms of the Regulation including the manner in which it is to be
disclosed, or that it contains any material misstatement.
Emphasis of Matter Paragraph
1. We draw attention to Note 3 to the Statement of Unaudited Financial Results, which describes the Scheme of
Amalgamation between Vitanosh Ingredients Private Limited (“Transferor Company”) and Lactose (India)
Limited (“Transferee Company”), sanctioned by the Hon’ble National Company Law Tribunal, vide its order
dated August 5th, 2026, with an Appointed Date of October 1, 2024, and which became effective on September
5th , 2026. As explained in the aforesaid note, the corresponding previous-period figures have been restated
to give effect to the amalgamation.
Our conclusion is not modified in respect of this matter.
For D M K H & Co
Chartered Accountants
Firm’s Registration No. 116886W
Shikha Kabra
Partner
Mem. No. 179437
UDIN: 26179437XYZLMA5196
Place: Mumbai
Date: November 14, 2026
LACT:
INDIA LIMITED
LACTOSE (INDIA) LIMITED
CIN: L15201GJ1991PLCO15186
Regd. Off. : Survey No.5, 6 & 7A, Village Poicha (Rania), Taluka Savii, District Vadodara, Gujarat - 391780
website :-www.lactoseindialimited.com, Email ID: li@lactoseindialimited.com, Telephone: 02246644333
Statement of Unaudited Financial Results for the Quarter and Half year ended 30th September 2026
(Rs. In Lakhs Except for EPS)
1|Revenue from operations
O[R te hv ee rn Iu ne
f or mo em operations
5,819.38 4,696.84 411813 10,516.22 8,075.69 16,329.01
209 38.14 2847 6023 58.32 66.87
Total income
5,841.47 4,734.98 4,146.60 10,576.44 8,134.01 16,395.88
2|Expenses
(a) Cost of materials consumed 3,888.76 3,249.18 222967 7,137.94 3,792.88 8,751.59
(b) Change in inventories of finished goods, work-in-progress
and stock-in-frade
511 (613.46) 7255 (608.35) 836.38 676.67
(c) Manufacturing Expenses 74261 790.18 706.90 1,532.80 1,330.09 257409
(d) Employees benefits expenses 41213 42513 359.40 831.26 710.24 1430.98
(e) Finance Costs 21384 164.46 98.89 37831 21764 483.96
(f) Depreciation and amortization expenses 18267 183.03 163.57 365.71 32013 661.52
(g) Other expenses 311.04 271.03 239.83 58207 465,86 1,124.89
Total Expenses 5756.16 446956 387082 1022574 767322 15,693.70
3| Profit(Loss) before tax 8531 265.43 27578 35074 460.79 70218
4|Tax Expense:
Current Tax (net) 291 9.07 47.06 11.98 7863 119.82
Deferred Tax (net) 37.83 11775 46,07 155.57 86.88 98.98
Tax of Earlier Years - - - - - (22.13)]
5{Net Profit/(loss) after tax 44.57 138.61 182.67 183.16 29528 505.51
6|Other Comprehensive Incomel(loss)
Items That will not be reclassified subsequently into Profit
or loss
Remeasurements of Defined Benefits Plan (Net of Tax) - * “ - - (1.03)]
Income tax effect - - - - < 031
7|Total Comprehensive income/(loss),net of tax (5+6) 44.57) 138.61 182.67 183.16 20528 504.79
Paid-up equity share capital (Face Value of Rs. 10 each) 1,258.90 1,258.90 1,258.90 1,258.90 1,258.90 1,258.90
9| Other Equity(excluding revaluation reserve) - - - - - 4,961.25
10[Earnings per share (of Rs. 10/- each)
(not annualised for the quarters)
(a) Basic (inRs.) 031 098 129 129
(b) Diluted (in Rs.) 031 09 1.26 1.28
*Restated pursuant to merger. Refer note no.3
103-104, First Floor, “A” Wing, Navbharat Estate, Zakaria Bunder Road, Sewri (W), Mumbai - 400015, India,
Tel. : +91-22-4664 4333 Email : lil@Iactoseindialimited.com Website : www.lactoseindialimited.com
Regd. Office : Survey No. 5, 6 & 7A, Village : Poicha (Rania), Taluka Savli, District : Vadodara, Gujarat - 391780, India.
CIN : L15201GJ1991PLC015186
LACT: IS=
INDIA LIMITED
LACTOSE (INDIA) LIMITED
R we eg bd s. i lO ef f. : -: wS wu w.r lv ae cy t oN so s. i5 n, d i6 a l& i m7 iA t, e dV cil ol ma ,g e E P moi ich Ia D :( R la in @i lz a) c, t T osa el iu nk da i aS la ivi mi i, t eD di .st cr oi mc ,t V Ta ed lo ed pha or na e, : G 0u 2j 2a 4r 8a 6t- 4 3 49 31 37 38 0
Notes:
1 AT uh de i ta ob ro sv oe f F ti hn ea Cnc oi ma pl aR nes yu l ht as vw ee cr ae r rif ee dv i oe uw te d fi mb iy t et dh e r A eud vit io C feo tm whm ei at bt oe ve e a n Fid n t ah ne cr iae la f Rt ee sr ua lp tp sr po uv re sd u aa nn td tt oa Rk ee gn u o lan t r ie oc no 3rd 3 b ofy t hth ee SB Eo Ba Ird ( Lo if s tD ii nr ge c Ot bo lr is g aa tt i t oh ne si r & m De ie st ci ln og s uh re el d R o en q u1 i4 rt eh m eN no tv se )m b Re egr u, l a2 t02 i6 o. n sT 2h 0e 1 5St ,a tutory
2. The Company operates in one reportable business seqment i e, *Phamnaceuticals'.
3 o(D p"u eTr rri aan n tg s i f vt e eh r e
[Showing first 8,000 characters — download PDF for full document]